Patents Examined by Kagnew H. Gebreyesus
  • Patent number: 11913045
    Abstract: The present invention provides engineered phenylalanine ammonia-lyase (PAL) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered phenylalanine ammonia-lyase (PAL) polypeptides.
    Type: Grant
    Filed: September 2, 2020
    Date of Patent: February 27, 2024
    Assignee: Codexis, Inc.
    Inventors: Gjalt W. Huisman, Nicholas J. Agard, Benjamin Mijts, Jonathan Vroom, Xiyun Zhang
  • Patent number: 11899015
    Abstract: Chimeric recombinant proteins for the detection of infection by Borreliella and/or diagnosis of Lyme disease are provided. Methods and devices for conducting immunoassays with the chimeric recombinant proteins are also provided.
    Type: Grant
    Filed: October 24, 2022
    Date of Patent: February 13, 2024
    Assignee: VIRGINIA COMMONWEALTH UNIVERSITY
    Inventor: Richard Marconi
  • Patent number: 11845970
    Abstract: The present invention provides for recombinant Endo-S2 mutants (named Endo-S2 glycosynthases) that exhibit reduced hydrolysis activity and increased transglycosylation activity for the synthesis of glycoproteins wherein a desired sugar chain is added to a fucosylated or nonfucosylated GlcNAc-IgG acceptor. As such, the present invention allows for the synthesis and remodeling of therapeutic antibodies thereby providing for certain biological activities, such as, prolonged half-life time in vivo, less immunogenicity, enhanced in vivo activity, increased targeting ability, and/or ability to deliver a therapeutic agent.
    Type: Grant
    Filed: May 14, 2021
    Date of Patent: December 19, 2023
    Assignee: University of Maryland, College Park
    Inventors: Lai-Xi Wang, Qiang Yang, Tiezheng Li, Xin Tong
  • Patent number: 11795488
    Abstract: The present invention relates to a method of ligating a first peptide via its C-terminus to the N-terminus of a second peptide, wherein the reaction is catalyzed by an asparagine/aspartate (Asx) peptide ligase OaAEPI Cys247Ala having the amino acid sequence of SEQ ID NO: 1. Further encompassed are a method of preparing a dimer, oligomer, or multimer of one or more peptides of interest and a method of modifying or tagging the surface of a target cell by one or more peptides of interest. Also encompassed in the invention are the ligated peptides and/or tagged target cells obtainable according to any of the methods, the peptide ligase OaAEPI Cys247Ala having the amino acid sequence of SEQ ID NO: 1, as well as kits comprising said peptide ligase.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: October 24, 2023
    Assignee: NANYANG TECHNOLOGICAL UNIVERSITY
    Inventors: Bin Wu, Renliang Yang, Yee Hwa Wong, Julien Lescar, Chuan Fa Liu, James P Tam, Kien Truc Giang Nguyen, Ziqi Long
  • Patent number: 11788092
    Abstract: Microorganisms are genetically engineered to produce 3-hydroxypropionate (3-HP). The microorganisms are carboxydotrophic acetogens. The microorganisms produce acetyl-coA using the Wood-Ljungdahl pathway for fixing CO/CO2. A ?-alanine pyruvate aminotransferase from a microorganism that contains such an enzyme is introduced. Additionally, an acetyl-coA carboxylase may also be introduced. The production of 3-HP can be improved. This can be effected by improved promoters or higher copy number or enzymes that are catalytically more efficient.
    Type: Grant
    Filed: February 7, 2022
    Date of Patent: October 17, 2023
    Assignee: LanzaTech, Inc.
    Inventors: Fungmin Liew, Michael Koepke
  • Patent number: 11788111
    Abstract: Non-naturally occurring tRNASec and methods of using them for recombinant expression of proteins engineered to include one or more selenocysteine residues are disclosed. The non-naturally occurring tRNASec can be used for recombinant manufacture of selenocysteine containing polypeptides encoded by mRNA without the requirement of an SECIS element. In some embodiments, selenocysteine containing polypeptides are manufactured by co-expressing a non-naturally occurring tRNASec a recombinant expression system, such as E. coli, with SerRS, EF-Tu, SelA, or PSTK and SepSecS, and an mRNA with at least one codon that recognizes the anticodon of the non-naturally occurring tRNASec.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: October 17, 2023
    Assignee: YALE UNIVERSITY
    Inventors: Dieter Soll, Takahito Mukai, Kyle Hoffman
  • Patent number: 11781124
    Abstract: Disclosed herein are recombinant polynucleotide sequences, vectors, host cells and methods for producing astaxanthin. The recombinant polynucleotide sequence is designed to provide a higher level of astaxanthin precursors via a shorter metabolic pathway, and thereby attains higher level of end products (e.g., astaxanthin) with desired stereoisomeric form and/or esterified form.
    Type: Grant
    Filed: November 10, 2020
    Date of Patent: October 10, 2023
    Assignee: ACADEMIA SINICA
    Inventors: Jui-Jen Chang, Caroline Thia, Hao-Yeh Lin, Yu-Ju Lin, Chieh-Chen Huang, Wen-Hsiung Li
  • Patent number: 11739128
    Abstract: The invention relates generally to methods for preparing recombinant nucleosomes. In particular, the invention relates to methods for ligating a histone peptide onto a fully assembled recombinant nucleosome. The invention further relates to modified core histone proteins, histone peptides to be ligated to the modified core histone proteins, and fully assembled recombinant nucleosomes and libraries of recombinant nucleosomes prepared by the methods of the invention.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: August 29, 2023
    Assignee: EPICYPHER, INC.
    Inventors: Martis William Cowles, Michael-Christopher Keogh, Jonathan M. Burg, Zu-Wen Sun
  • Patent number: 11719696
    Abstract: The invention includes, in part, methods and compounds for diagnosing diseases and conditions characterized by altered threonyl-tRNA synthetase (TARS) activity, which include, but are not limited to diseases and conditions in which angiogenesis is altered. In some embodiments of the invention, a level of a TARS molecule is determined and compared to a control level of TARS to assess onset, progression, and/or regression of a disease or condition associated with altered TARS activity.
    Type: Grant
    Filed: October 11, 2020
    Date of Patent: August 8, 2023
    Assignee: The University of Vermont and State Agricultural College
    Inventors: Christopher Francklyn, Karen M. Lounsbury, Tamara Williams
  • Patent number: 11718839
    Abstract: A composition and method for preventing and treating infections caused by enveloped viruses, such as SARS-CoV-2 virus. The invention includes compounds having a catalytic domain of a glycosidase and a binding domain that binds the compound to the surface of the targeted virus. The invention also includes a pharmaceutical formulation comprising the compound and a pharmaceutically acceptable carrier to deliver the active portion of the compound to the infecting virus within an infected human or animal. The pharmaceutical formulation can be an inhalant or a nasal spray to the infected human or animal. The invention also includes methods of using a glycosidase or the catalytic part of a glycosidase to deactivate enveloped virus by removing glycans from the viral surface protein.
    Type: Grant
    Filed: July 16, 2021
    Date of Patent: August 8, 2023
    Assignee: ILLINOIS INSTITUTE OF TECHNOLOGY
    Inventors: Oscar Juarez, Karina Tuz, David Do Le Minh
  • Patent number: 11702462
    Abstract: The present disclosure provides for non-viral compositions and methods for delivering nucleic acids into eukaryotic cells (e.g., stem cells) with high efficiency and low genotoxicity.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: July 18, 2023
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Arash Hatefi, Xuguang Chen, Alireza Nomani
  • Patent number: 11674160
    Abstract: Methods, systems and compositions for producing at least one light-boiling, volatile, organic product using at least a portion of one or more carbon containing substances from a non-biosynthetic process in a biosynthetic process are provided. These methods, systems and compositions are useful in reducing waste treatment load of carbon containing chemical process waste streams.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: June 13, 2023
    Assignee: INV NYLON CHEMICALS AMERICAS, LLC
    Inventors: Gary Smith, Paul S. Pearlman, Gregory S. Kirby
  • Patent number: 11674164
    Abstract: Periplasmic fusion proteins comprising a binding motif attached to a C-terminus of a first protein or embedded within an amino acid sequence of the first protein, nucleic acid constructs encoding the periplasmic fusion proteins, vectors comprising the nucleic acid constructs, and methods of producing the periplasmic fusion proteins are provided. Also provided are protease deficient host cells for producing the periplasmic fusion proteins.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: June 13, 2023
    Assignee: BIO-RAD ABD SEROTEC GMBH
    Inventors: Christian-Michael Aloisius Heinz Hentrich, Francisco Ylera, Hans Joachim Knappik
  • Patent number: 11661611
    Abstract: The present disclosure is in the field of genome engineering, particularly targeted genetic modification of a CISH gene.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: May 30, 2023
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Anthony Conway, Gary K. Lee
  • Patent number: 11661618
    Abstract: Recombinant bacterial cells are provided that comprise a stable non-canonical amino acid translation pathway. In some aspects, the bacteria comprise nucleic acids encoding a non-canonical amino acid translation pathway (e.g., a tRNA for incorporation of a non-canonical amino acid, such selenocysteine); a marker polypeptide that includes the non-canonical amino acid. Recombinant tRNA and selection marker coding sequences are likewise provided.
    Type: Grant
    Filed: February 10, 2020
    Date of Patent: May 30, 2023
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Andrew D. Ellington, Ross Thyer
  • Patent number: 11566271
    Abstract: The present invention relates to processes to make neosaxitoxin, and analogues and variants thereof, and intermediates in the production of neosaxitoxin in recombinant host cells. Neosaxitoxin and the analogues and variants thereof may be used in the production of pharmaceutical compositions.
    Type: Grant
    Filed: October 19, 2020
    Date of Patent: January 31, 2023
    Assignees: Vestlandets Innovasjonsseiskap AS, Newsouth Innovations Pty Limited
    Inventors: Ralf Kellmann, Brett Neilan
  • Patent number: 11535838
    Abstract: Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.
    Type: Grant
    Filed: June 15, 2020
    Date of Patent: December 27, 2022
    Assignee: Research Development Foundation
    Inventors: Michael G. Rosenblum, Khalid Amanali Mohamedali, Lawrence H. Cheung
  • Patent number: 11525132
    Abstract: Ligase mutants of the following (1), (2), or (3): (1) a ligase mutant comprising an amino acid sequence showing 95% or more identity to the amino acid sequence of SEQ ID NO: 1, and having a nucleic acid-linking activity; (2) a ligase mutant comprising an amino acid sequence showing 90% or more identity to the amino acid sequence of SEQ ID NO: 2, and having a nucleic acid-linking activity; or (3) a ligase mutant comprising an amino acid sequence showing 97% or more identity to the amino acid sequence of SEQ ID NO: 3, and having a nucleic acid-linking activity, have excellent properties.
    Type: Grant
    Filed: March 23, 2021
    Date of Patent: December 13, 2022
    Assignee: AJINOMOTO CO., INC.
    Inventors: Miwa Konishi, Shohei Kajimoto, Yusuke Hagiwara, Yasuhiro Mihara, Shogo Nakano, Tomoharu Motoyama, Sohei Ito
  • Patent number: 11497209
    Abstract: The present disclosure relates to a synthetic Túngara frog foam composition. The synthetic Túngara frog foam composition comprises six synthetically synthesized ranaspumin proteins (RSN-1 to RSN-6) wherein only the active segments of the RSN proteins are synthesized and six synthetically synthesized polysaccharides comprising four tetrasaccharides, a heptasaccharide and a nonasaccharide. Multiple novel applications of the foam are described.
    Type: Grant
    Filed: June 29, 2020
    Date of Patent: November 15, 2022
    Assignee: 1283581 BC LTD
    Inventor: Robert Scott McKinley
  • Patent number: 11492608
    Abstract: The invention relates to archaeal pyrrolysyl tRNA synthetases lacking a nuclear localization signal and/or comprising a nuclear export signal. The invention also relates to polynucleotides encoding said pyrrolysyl tRNA synthetases, eukaryotic cells comprising said polynucleotide and tRNA acylated by the pyrrolysyl tRNA synthetase or a polynucleotide encoding such tRNA, methods utilizing said cells for preparing polypeptides comprising unnatural amino acid residues, and kits useful in said methods.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: November 8, 2022
    Assignee: European Molecular Biology Laboratory
    Inventors: Edward Lemke, Ivana Nikic, Gemma Estrada Girona, Christine Köhler